Current Report Filing (8-k)
August 22 2018 - 3:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): August 22, 2018
CV SCIENCES,
INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
000-54677
(Commission File Number)
|
80-0944970
(I.R.S. Employer Identification No.)
|
2688 South Rainbow Boulevard, Suite B
Las Vegas, Nevada 89146
(Address
of principal executive offices)
(866) 290-2157
(Registrant’s telephone number, including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
[_] Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[_] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[_] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company [_]
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 8.01 Other
Events.
On August 22, 2018, CV Sciences, Inc. (the
“Company”) issued a press release announcing that fully repaid the promissory note payable (“Promissory Note”)
to Wiltshire, LLC in cash, thus avoiding any remaining interest payments due on the Promissory Note. The Company issued the Promissory
Note on November 9, 2017 in the principal amount of $850,000, with an original due date of May 9, 2019.
A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial
Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: August 22, 2018
|
CV SCIENCES, INC.
|
|
|
|
|
|
By:
/s/ Joseph Dowling
|
|
Joseph Dowling
|
|
Chief Executive Officer and Chief Financial Officer
|
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From Sep 2023 to Sep 2024